PWP1's Expression in Gastric Cancer.

NCT06392750 | Completed

• 1 other identifier: mj2404001
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Background：Gastric cancer is a globally important disease and the fifth most diagnosed malignant cancer in the world. Because it is usually diagnosed at an advanced stage, gastric cancer has a high mortality rate, making it the third most common cause of cancer-related death. Hot spots of gastric cancer incidence and mortality exist in East Asia, Eastern Europe and South America. It is still an urgent problem to find new diagnostic and prognostic markers and better understand the molecular mechanism of gastric cancer. Although radical resection and systemic chemotherapy have shown great improvement, the prognosis of gastric cancer (GC) patients is still depressing due to malignant proliferation and metastasis. Therefore, it is urgent to clarify the potential molecular mechanism of gastric cancer progression, which will contribute to the development of targeted therapy. Effective induction of tumor cell apoptosis is the most important feature of a new chemical agent for cancer treatment. There is increasing evidence that the cell cycle can act in concert with apoptosis to cause cell death under certain cellular stress conditions. A comprehensive understanding of the relationship between apoptosis and cell cycle is essential for developing effective cancer therapies. PWP1 is also known as endonuclein, which contains five WD40 repeated domains and belongs to the WD40-repeated superfamily. It is highly expressed in human pancreatic adenocarcinoma, where it functions as a cell-cycle regulator. However, the normal function of Pwp1 is largely unknown. Previous research data show that PWP1 plays a key role in regulating biological functions such as RNA processing, signal transduction, gene expression, vesicle transport, cytoskeleton assembly and cell cycle progression. Whether the high expression of PWP1 is ubiquitous in tumors, the relationship between the high expression and clinicopathological factors of tumors, and the mechanism of PWP1 in tumors are still unclear. Further exploration of the molecular mechanism of PWP1 in GC may provide new ideas and therapeutic targets for GC treatment in the future, and benefit clinical patients.

Conditions

Diagnosis; Gastric Cancer

Keywords

gastric cancer; PWP1; IHC; expression

Outcome Measures

Primary Outcomes (1)

• The expression of PWP1 in adjacent tissues and tumor tissues of patients with gastrectomy for gastric cancer.

  Test the expression of PWP1 in adjacent tissues and tumor tissues of patients with gastrectomy for gastric cancer through the immunohistochemical.

  6 to 12 months after operation

Study Arms (2)

adjacent tissues

Paraffin tissue microarray slides prepared from normal tissue adjacent to tumor tissue removed during gastrectomy were retrieved from the biological sample library of the Northern Jiangsu People's Hospital.

tumor tissues

Paraffin tissue microarray slides prepared from tumor tissue removed during gastrectomy were retrieved from the biological sample library of the Northern Jiangsu People's Hospital.

Behavioral: Collection of tumor tissue specimens

Interventions

Collection of tumor tissue specimens BEHAVIORAL

Collection of tumor tissue specimens during surgery

tumor tissues

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

A total of 200 gastric cancer patients, including 80 (40.0%) men and 120(60.0%) women, were enrolled in this study.

You may qualify if:

• Diagnosed as gastric cancer
• Performing gastric cancer resection surgery
• Informed consent signed prior to surgery.

You may not qualify if:

• Emergency surgery
• Preoperative and intraoperative detection of distant organ metastases or extensive
• No standard chemotherapy for tumor-node-metastasis (TNM) staging II or III after surgery
• Incomplete case data.

Sponsors & Collaborators

• Northern Jiangsu People's Hospital: lead

Study Sites (1)

Northern Jiangsu People's Hospital Affiliated to Yangzhou University, General Surgery Institute of Yangzhou, Yangzhou University , Yangzhou

Yangzhou, Jiangsu, 225001, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Apply to the biological sample library for samples of tumor tissue and adjacent tissues preserved during surgery in gastric cancer patients. Subsequently, prepare tissue slices for immunohistochemical staining and compare the expression profiles between the two sample groups.

MeSH Terms

Conditions

Disease; Stomach Neoplasms

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Study Officials

• Daorong Wang, M.D., Professor

  Northern Jiangsu People's Hospital

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor, M.D.

Study Record Dates

• First Submitted: April 26, 2024
• First Posted: April 30, 2024
• Study Start: May 1, 2021
• Primary Completion: October 30, 2023
• Study Completion: April 1, 2024
• Last Updated: April 30, 2024

Record last verified: 2024-04

Locations

CN (1)